new glp 1 drug retatrutide ππ₯ Retatrutide: The Most Powerful Weight-Loss Yet? π§¬π Phase 3 clinical results are turning heads retatrutide, a next-generation triple-agonist targeting GLP-1, GIP and glucagon receptors, is showing unmatched levels of A new wave of weight-loss
Description
After sitting through long wait times at the labs followed by watching many different phlebotomists, many new to the job, struggle to find his veins, often poking him multiple times, as a seasoned phlebotomist, Liz decided to draw his blood at home and hand deliver it to the lab myself
References 1.Nauck MA, et al
By addressing both weight and blood sugar levels, GLP-1 therapy provides a comprehensive approach to diabetes management
The improved regulation of glycemia by GLP-1RA, along with their ability to reduce lipid synthesis, enhanced beta oxidation of free fatty acids and autophagy of fat cells contributes to their lipid modulation properties (59)
Phase 4 - Maintenance Dose: 0.25 to 1.0 mg weekly
Research-Use Only Notice 18+ only
